Cargando…
Weight-centric treatment of depression and chronic pain
BACKGROUND: Depression and chronic pain are two major chronic non-communicable diseases (CNCD). Considering the bidirectional relationship between obesity and CNCD, it is of the utmost importance to understand the effect of medications utilized to treat these diseases on body weight. METHODS: This i...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10661995/ https://www.ncbi.nlm.nih.gov/pubmed/37990725 http://dx.doi.org/10.1016/j.obpill.2022.100025 |
_version_ | 1785148502339223552 |
---|---|
author | Ghusn, Wissam Bouchard, Celeste Frye, Mark A. Acosta, Andres |
author_facet | Ghusn, Wissam Bouchard, Celeste Frye, Mark A. Acosta, Andres |
author_sort | Ghusn, Wissam |
collection | PubMed |
description | BACKGROUND: Depression and chronic pain are two major chronic non-communicable diseases (CNCD). Considering the bidirectional relationship between obesity and CNCD, it is of the utmost importance to understand the effect of medications utilized to treat these diseases on body weight. METHODS: This is a clinical review on the effect of medications for depression and chronic pain on body weight. We searched PubMed, Scopus, MEDLINE, and Google Scholar databases for studies on the topic from January 1, 1950 to April 1, 2022 in English language. Additionally, we present expert opinions in the fields of obesity, depression and chronic pain, providing a weight-centric approach to treat depression and chronic pain. RESULTS: Several antidepressant and chronic pain medications are associated with weight gain. Selective serotonin reuptake inhibitors, serotonin and norepinephrine reuptake inhibitors, tricyclic antidepressants, monoamine oxidases, mirtazapine and trazodone are common antidepressants that can increase body weight while bupropion is significantly associated with weight loss. Gabapentin and pregabalin are common chronic pain medications that are linked to weight gain. On the other hand, topiramate is associated with significant weight loss. Obesity, depression and chronic pain experts recommend avoiding medications that can increase body weight if another effective alternative is available. CONCLUSION: By shifting prescribing practices toward a weight-conscious approach (i.e., switching from weight gain medications to weight loss/neutral), it is possible to mitigate the incidence of drug-induced weight gain. |
format | Online Article Text |
id | pubmed-10661995 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Elsevier |
record_format | MEDLINE/PubMed |
spelling | pubmed-106619952023-11-21 Weight-centric treatment of depression and chronic pain Ghusn, Wissam Bouchard, Celeste Frye, Mark A. Acosta, Andres Obes Pillars Review BACKGROUND: Depression and chronic pain are two major chronic non-communicable diseases (CNCD). Considering the bidirectional relationship between obesity and CNCD, it is of the utmost importance to understand the effect of medications utilized to treat these diseases on body weight. METHODS: This is a clinical review on the effect of medications for depression and chronic pain on body weight. We searched PubMed, Scopus, MEDLINE, and Google Scholar databases for studies on the topic from January 1, 1950 to April 1, 2022 in English language. Additionally, we present expert opinions in the fields of obesity, depression and chronic pain, providing a weight-centric approach to treat depression and chronic pain. RESULTS: Several antidepressant and chronic pain medications are associated with weight gain. Selective serotonin reuptake inhibitors, serotonin and norepinephrine reuptake inhibitors, tricyclic antidepressants, monoamine oxidases, mirtazapine and trazodone are common antidepressants that can increase body weight while bupropion is significantly associated with weight loss. Gabapentin and pregabalin are common chronic pain medications that are linked to weight gain. On the other hand, topiramate is associated with significant weight loss. Obesity, depression and chronic pain experts recommend avoiding medications that can increase body weight if another effective alternative is available. CONCLUSION: By shifting prescribing practices toward a weight-conscious approach (i.e., switching from weight gain medications to weight loss/neutral), it is possible to mitigate the incidence of drug-induced weight gain. Elsevier 2022-06-23 /pmc/articles/PMC10661995/ /pubmed/37990725 http://dx.doi.org/10.1016/j.obpill.2022.100025 Text en © 2022 The Authors https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). |
spellingShingle | Review Ghusn, Wissam Bouchard, Celeste Frye, Mark A. Acosta, Andres Weight-centric treatment of depression and chronic pain |
title | Weight-centric treatment of depression and chronic pain |
title_full | Weight-centric treatment of depression and chronic pain |
title_fullStr | Weight-centric treatment of depression and chronic pain |
title_full_unstemmed | Weight-centric treatment of depression and chronic pain |
title_short | Weight-centric treatment of depression and chronic pain |
title_sort | weight-centric treatment of depression and chronic pain |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10661995/ https://www.ncbi.nlm.nih.gov/pubmed/37990725 http://dx.doi.org/10.1016/j.obpill.2022.100025 |
work_keys_str_mv | AT ghusnwissam weightcentrictreatmentofdepressionandchronicpain AT bouchardceleste weightcentrictreatmentofdepressionandchronicpain AT fryemarka weightcentrictreatmentofdepressionandchronicpain AT acostaandres weightcentrictreatmentofdepressionandchronicpain |